Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders such as Alzheimers disease (AD).
Type:
Application
Filed:
December 11, 2020
Publication date:
September 23, 2021
Applicant:
H. Lundbeck A/S
Inventors:
Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Tina Stummann, Arnout Gerritsen, Edward van den Brink, Paul Parren, Esben Trabjerg, Kasper Dyrberg Rand
Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Embodiments of this invention relate to the binding fragments of antibodies described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.
Type:
Grant
Filed:
December 9, 2019
Date of Patent:
September 14, 2021
Assignee:
H. LUNDBECK A/S
Inventors:
Andrew Lawrence Feldhaus, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katie Olson Anderson, Ethan Wayne Ojala, Pei Fan, Charlie Karasek, Jenny A. Mulligan, Danielle Marie Mitchell, Patricia Dianne McNeill, Michelle L. Scalley-Kim, Erica Stewart, Jeffrey T. L. Smith, John Latham
Abstract: The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
Type:
Grant
Filed:
May 12, 2020
Date of Patent:
September 7, 2021
Assignee:
H. Lundbeck A/S
Inventors:
Klaus Gjervig Jensen, Lisbet Kværnø, Morten Jørgensen, Martin Juhl
Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
Type:
Grant
Filed:
September 27, 2019
Date of Patent:
September 7, 2021
Assignee:
H. Lundbeck A/S
Inventors:
Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
Abstract: The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below and salts thereof The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease. The invention also relates to new intermediates of said process.
Type:
Grant
Filed:
May 18, 2020
Date of Patent:
September 7, 2021
Assignee:
H. Lundbeck A/S
Inventors:
Martin Juhl, Frans Dennis Therkelsen, Tobias Gylling Frihed
Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.
Type:
Grant
Filed:
January 15, 2019
Date of Patent:
September 7, 2021
Assignee:
H. LUNDBECK A/S
Inventors:
Brian Robert Kovacevich, Leon F. Garcia-Martinez, Katie Olson Anderson, Benjamin H. Dutzar, Jens J. Billgren, John A. Latham, Danielle M. Mitchell, Patricia Dianne McNeill, Nicole M. Janson, Maria-Cristina Loomis
Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful correcting a deficient level progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
Type:
Application
Filed:
November 13, 2020
Publication date:
September 2, 2021
Applicant:
H. Lundbeck A/S
Inventors:
Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Arnout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
Abstract: The present invention provides 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
Type:
Grant
Filed:
December 3, 2019
Date of Patent:
August 31, 2021
Assignee:
H. Lundbeck A/S
Inventors:
Karsten Juhl, Mikkel Jessing, Morten Langgård, Paulo Jorge Vieira Vital, Mauro Marigo, Jan Kehler, Lars Kyhn Rasmussen
Abstract: The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]guinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below and pharmaceutically acceptable salts thereof The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease. The invention also relates to a new intermediate of said process.
Type:
Grant
Filed:
May 18, 2020
Date of Patent:
August 31, 2021
Assignee:
H. Lundbeck A/S
Inventors:
Martin Juhl, Lisbet Kværnø, Mikkel Fog Jacobsen
Abstract: The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
Type:
Application
Filed:
October 26, 2020
Publication date:
August 5, 2021
Applicant:
H. Lundbeck A/S
Inventors:
Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing, Karsten Juhl, Paulo Jorge Vieira Vital
Abstract: The invention relates to combinational treatment using a monoclonal anti-alpha-synuclein antibody and an additional medicament. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy together with another medicament of the invention.
Abstract: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
Type:
Grant
Filed:
November 4, 2019
Date of Patent:
July 13, 2021
Assignee:
H. Lundbeck A/S
Inventors:
Morten Jorgensen, Peter Hongaard Andersen, Klaus Gjervig Jensen
Abstract: Provided herein are spirocyclic and fused bicyclic carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
Type:
Grant
Filed:
November 15, 2017
Date of Patent:
July 13, 2021
Assignee:
H. LUNDBECK A/S
Inventors:
Cheryl A. Grice, Daniel J. Buzard, Michael B. Shaghafi
Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.
Type:
Application
Filed:
January 8, 2021
Publication date:
July 8, 2021
Applicant:
H. Lundbeck A/S
Inventors:
Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Alfred Daechsel, Ayodeji Abdur-rasheed Asuni, Nina Helen Rosenqvist, Christiane Volbracht, Lone Helboe, Anders Brandt, Florence Sotty, Søren Christensen, Jeffrey B. Stavenhagen
Abstract: Provided herein are methods of treating inflammation or neuropathic pain using an effective dose of a monoacylglycerol lipase inhibitor or a composition thereof.
Type:
Grant
Filed:
September 6, 2019
Date of Patent:
June 15, 2021
Assignee:
H. LUNDBECK A/S
Inventors:
Jacqueline Lorayne Blankman, Jason Robert Clapper, R. Alan B. Ezekowitz, Iain Peter Fraser, Cheryl A. Grice, Todd K. Jones, Gary Paul O'Neill, Archie Wayne Thurston, Jr., Channing Rodney Beals
Abstract: The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.
Type:
Grant
Filed:
February 13, 2019
Date of Patent:
June 8, 2021
Assignees:
The University of Iowa Research Foundation, H. LUNDBECK A/S
Inventors:
Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian R. Kovacevich, John Latham, Jeffrey T. L. Smith, Leon F. Garcia-Martinez
Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (1) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
Type:
Grant
Filed:
October 1, 2020
Date of Patent:
June 8, 2021
Assignee:
H. Lundbeck A/S
Inventors:
Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
Type:
Grant
Filed:
October 1, 2020
Date of Patent:
June 8, 2021
Assignee:
H. Lundbeck A/S
Inventors:
Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
Abstract: The present invention is based on antibodies which are both highly specific for hyperphosphorylated pathogenic P-S396 tau and highly specific for labelled sections of the human retina, as well as to methods of using these antibodies and their tau binding fragments in the treatment of retinoid amyloidosis, age related macular degeneration (ARMD), and glaucoma.
Type:
Grant
Filed:
January 3, 2018
Date of Patent:
May 4, 2021
Assignee:
H. Lundbeck A/S
Inventors:
Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Daechsel, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist